Skip to main content

Integrity Implants and Fusion Robotics Merge to Form Accelus

Written by Customer Service on . Posted in Mergers And Acquisitions.

Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine

PALM BEACH GARDENS, Fla., July 06, 2021 (GLOBE NEWSWIRE) — Integrity Implants Inc., a privately held medical device company focused on Adaptive Geometry™ technology designed to enable MIS spine surgery, and Fusion Robotics, LLC, a privately held medical technology company focused on efficient and cost-effective navigation and robotic targeting solutions for spine surgery, today announced that they have consummated a merger combining the two companies. The combined company will be re-branded as “Accelus” and is uniquely positioned to accelerate the adoption of minimally invasive surgery as the standard of care in spine.

“Accelus will create opportunities for wide-scale adoption of robotics in spine surgery—both in hospitals and ambulatory surgery centers (ASCs)—by addressing previous constraints related to cost and efficiency,” said Chris Walsh, who will serve as the CEO of Accelus. “Both Fusion Robotics and Integrity Implants have built enabling technology platforms that create a force multiplier for spinal care. Our products and culture create accessibility to fit each patient’s anatomy, each surgeon’s preferred approach, and each healthcare facility’s space and budget limitations, embodying our core principle of access without compromise.”

Although the benefits of MIS have been recognized for decades, broad adoption in the spine market is still constrained relative to other orthopedic and interventional procedures. The combination of Fusion Robotics’ efficient, compact and scalable robot with Integrity Implant’s unique Adaptive Geometry implants will enable the rapid acceleration of MIS adoption.

“We believe Accelus is poised to be the next dominant player in the spine market,” said Alex Lukianov, who will serve as Chairman of the company’s Board of Directors. “Accelus will uniquely accelerate penetration of MIS while fostering a culture of outstanding performance together with an unparalleled product development engine to continually simplify surgical procedures. Our growth prospects are tremendous. Onward and upward!”

Integrity Implants’ flagship FlareHawk® Lumbar Interbody Fusion Device received FDA clearance in 2016 and CE mark approval in 2021, and to date more than 10,500 FlareHawk devices have been implanted in more than 8,000 patients. Integrity Implants also holds FDA clearances for its LineSider® Spinal System, FlareHawk TiHawk™ Interbody Fusion System and Toro™-L Interbody Fusion System. Fusion Robotics received a 510(k) clearance for its initial product offering and started performing spine procedures in the U.S. market earlier this year.

“This combination of teams and technology represents a transformative opportunity to accelerate innovation in spine,” said neurosurgeon Kevin Foley, M.D., Chief Robotics Officer of Fusion Robotics. “The implant portfolio is complementary to the robotics platform, and with the rapid strides we are making in robotics development—specifically related to our fluoroscopy-based robotics system—the synergies will become even more robust in the coming months.”

Accelus’ corporate office, R&D, distribution and Accelus Clinical Education (ACE) surgeon training facility will be headquartered in Palm Beach Gardens, Fla. Additional ACE labs and R&D centers will be located in Boulder, Colo. and San Diego, Calif.

The company’s Executive Management Team will consist of leaders from both Integrity Implants and Fusion Robotics, who bring decades of experience and leadership across spine, navigation and surgical robotics. Accelus’s Board of Directors will be composed of Fusion Robotics’ founders Alex Lukianov and Brad Clayton; Integrity Implants’ founders Chris Walsh and Wyatt Geist; and current Integrity Implants Directors Nate Ward, Ned Lipes and Paul Birkmeyer.

“The organizational synergies go beyond products and technology, as we are pulling together the ‘A-team’ of spine,” Walsh added.

Accelus will be showcasing its current product portfolio during the 2021 Spine Summit meeting in San Diego this July and the 2021 Annual Scientific Meeting of the American Association of Neurological Surgeons in Orlando in August, as well as unveiling new product launches at the North American Spine Society’s 36th Annual Meeting in Boston this fall.

About Accelus

Accelus is committed to accelerating minimally invasive spine surgery through its procedure-enabling technology with broad accessibility to previously underserved markets. Founded in 2021 through the combination of Integrity Implants and Fusion Robotics, the company is focused on providing its proprietary Adaptive Geometry™ technology with pragmatic and economical navigation and robotic solutions with broad clinical use in spine surgery.

Media Contact: Brandy Craig
Phone: 305-676-1679
bcraig@integrityimplants.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.